Trials / Completed
CompletedNCT00909961
A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
A One Year, Local, Open Label, Multicentre Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on BMD and Biochemical Markers of Bone in PMO Pts Between the Ages of 50 and 65 Years
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 50 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effects of zoledronic acid 5 mg infusion on BMD and biochemical markers of bone in post-menopausal osteoporotic patients aged between 50-65.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic acid |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-16
- First posted
- 2009-05-29
- Last updated
- 2017-03-21
Locations
6 sites across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00909961. Inclusion in this directory is not an endorsement.